Neotaxan (Paclitaxel)

Neotaxan (paclitaxel) is a taxane chemotherapy used for solid tumours that rely on microtubule dynamics.

• Breast cancer: improves progression‑free and overall survival when combined with standard regimens.
• Ovarian cancer: enhances response rates in first‑line and recurrent settings.
• Non‑small cell lung cancer: provides disease control as part of combination therapy.
• Kaposi sarcoma: reduces lesion burden and disease progression in advanced cases.

• Paclitaxel binds to the β‑tubulin subunit of microtubules, stabilizing them and preventing depolymerisation. This blockade arrests cells in the G2/M phase of the cell cycle, inhibiting mitotic spindle formation and ultimately leading to apoptosis of rapidly dividing cancer cells.

Paclitaxel is associated with a range of adverse reactions that vary in frequency and severity.

Common Side Effects

• Neutropenia: reduced white blood cell count increasing infection risk.
• Alopecia: hair loss that is usually reversible after treatment.
• Peripheral neuropathy: tingling or numbness in extremities.
• Fatigue: generalized tiredness affecting daily activities.
• Nausea and vomiting: gastrointestinal upset common with chemotherapy.
• Myalgia: muscle pain or cramps.

Serious or Rare Side Effects

• Severe hypersensitivity reactions: including anaphylaxis during infusion.
• Febrile neutropenia: fever with low neutrophil count requiring urgent care.
• Cardiac arrhythmias: irregular heart rhythms observed during infusion.
• Severe peripheral neuropathy: may become permanent.
• Pulmonary toxicity: rare interstitial lung disease.
• Hepatotoxicity: significant liver enzyme elevations.

Use of Neotaxan requires careful monitoring and patient assessment before and during therapy.

• Blood count monitoring: perform complete blood counts before each cycle to detect neutropenia.
• Cardiac evaluation: assess baseline ECG and monitor for arrhythmias during infusion.
• Hypersensitivity risk: pre‑medicate with corticosteroids and antihistamines to reduce infusion reactions.
• Liver function: avoid in patients with severe hepatic impairment; adjust dose if needed.
• Contraception: advise both male and female patients of reproductive potential to use effective contraception during treatment and for a defined period after.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake the vial.

Paclitaxel may interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Strong CYP2C8 inhibitors (e.g., gemfibrozil): increase paclitaxel exposure and toxicity.
• Potent CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): raise plasma concentrations, heightening adverse effects.
• Concurrent myelosuppressive agents: compound bone‑marrow suppression, raising infection risk.

Moderate Interactions (Monitor Closely)

• CYP3A4 inducers (e.g., rifampin, carbamazepine): reduce paclitaxel levels, potentially decreasing efficacy.
• Anticoagulants (e.g., warfarin, DOACs): may increase bleeding tendency.
• Corticosteroids: can mitigate hypersensitivity but may also affect immune response.